Zhejiang Orient Gene Biotech Co., Ltd

SHSE:688298 Stock Report

Market Cap: CN¥5.9b

Zhejiang Orient Gene Biotech Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Xiaoliang Fang

Chief executive officer

CN¥907.2k

Total compensation

CEO salary percentagen/a
CEO tenure7.7yrs
CEO ownershipn/a
Management average tenure7.7yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Zhejiang Orient Gene Biotech Co., Ltd's (SHSE:688298) Price

Dec 17
Subdued Growth No Barrier To Zhejiang Orient Gene Biotech Co., Ltd's (SHSE:688298) Price

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Aug 20
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Weighed On By Its Debt Load?

Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

Apr 30
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) A Risky Investment?

CEO

Xiaoliang Fang (67 yo)

7.7yrs

Tenure

CN¥907,200

Compensation

Mr. Xiaoliang Fang is GM & Director of Zhejiang Orient Gene Biotech Co., Ltd. from April 18, 2017.


Leadership Team

NamePositionTenureCompensationOwnership
Xiaoliang Fang
GM & Director7.7yrsCN¥907.20kno data
Jinhong Yu
Deputy GM & Financial Manager7.7yrsCN¥890.30k0.078%
CN¥ 4.6m
Pang Qi
Deputy General Manager7.7yrsCN¥729.60k0.078%
CN¥ 4.6m
Jinfeng Tan
Deputy General Manager7.7yrsCN¥834.60k0.078%
CN¥ 4.6m
Chunmei Zhong
Deputy General Manager7.7yrsCN¥737.30k0.078%
CN¥ 4.6m
Faying Xu
Deputy General Manager7.7yrsCN¥730.30k0.078%
CN¥ 4.6m

7.7yrs

Average Tenure

51yo

Average Age

Experienced Management: 688298's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiaoliang Fang
GM & Director7.7yrsCN¥907.20kno data
Jianqiu Fang
Chairman7.7yrsCN¥1.47mno data
Bo Li
Independent Director1.3yrsCN¥33.70kno data

7.7yrs

Average Tenure

45yo

Average Age

Experienced Board: 688298's board of directors are considered experienced (7.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 18:44
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zhejiang Orient Gene Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yiling ChenGuosen Securities Co., Ltd.
Hanqing ZhuGuosen Securities Co., Ltd.